阿尔茨海默病的免疫疗法。
Immunotherapy for Alzheimer disease.
机构信息
Department of Neurology and Neuroscience, Weill Cornell Medical College, New York, NY 10065, USA.
出版信息
MAbs. 2009 Mar-Apr;1(2):112-4. doi: 10.4161/mabs.1.2.7829. Epub 2009 Mar 11.
Abstract
Immunotherapy approaches for Alzheimer disease currently are among the leading therapeutic directions for the disease. Active and passive immunotherapy against the beta-amyloid peptides that aggregate and accumulate in the brain of those afflicted by the disease have been shown by numerous groups to reduce plaque pathology and improve behavior in transgenic mouse models of the disease. Several ongoing immunotherapy clinical trials for Alzheimer disease are in progress. The background and ongoing challenges for these immunological approaches for the treatment of Alzheimer disease are discussed.
摘要
阿尔茨海默病的免疫疗法目前是该病的主要治疗方向之一。许多研究小组已经证明，针对在疾病患者大脑中聚集和积累的β-淀粉样肽的主动和被动免疫疗法可以减少斑块病理，并改善疾病转基因小鼠模型的行为。目前正在进行几项针对阿尔茨海默病的免疫疗法临床试验。本文讨论了这些用于治疗阿尔茨海默病的免疫方法的背景和当前挑战。
相似文献
1
Immunotherapy for Alzheimer disease.
MAbs. 2009 Mar-Apr;1(2):112-4. doi: 10.4161/mabs.1.2.7829. Epub 2009 Mar 11.
2
Tau passive immunization inhibits not only tau but also Aβ pathology.
Alzheimers Res Ther. 2017 Jan 10;9(1):1. doi: 10.1186/s13195-016-0227-5.
3
[Development of antibodies for immunotherapy of Alzheimer's disease].
Rinsho Shinkeigaku. 2012;52(11):1168-70. doi: 10.5692/clinicalneurol.52.1168.
4
Clinical trials of amyloid-based immunotherapy for Alzheimer's disease: end of beginning or beginning of end?
Expert Opin Biol Ther. 2013 Nov;13(11):1515-22. doi: 10.1517/14712598.2013.838555. Epub 2013 Sep 22.
5
Immunotherapy for Alzheimer's disease: from anti-β-amyloid to tau-based immunization strategies.
Immunotherapy. 2012 Feb;4(2):213-38. doi: 10.2217/imt.11.170.
6
A beta immunotherapy: Lessons learned for potential treatment of Alzheimer's disease.
Neurodegener Dis. 2005;2(5):255-60. doi: 10.1159/000090365.
7
Passive Immunotherapies Targeting Amyloid Beta and Tau Oligomers in Alzheimer's Disease.
J Pharm Sci. 2020 Jan;109(1):68-73. doi: 10.1016/j.xphs.2019.10.024. Epub 2019 Oct 21.
8
Active full-length DNA Aβ immunization in 3xTg-AD mice reduces not only amyloid deposition but also tau pathology.
Alzheimers Res Ther. 2018 Nov 20;10(1):115. doi: 10.1186/s13195-018-0441-4.
9
Amyloid reduction by amyloid-beta vaccination also reduces mouse tau pathology and protects from neuron loss in two mouse models of Alzheimer's disease.
J Neurosci. 2009 Jun 24;29(25):7957-65. doi: 10.1523/JNEUROSCI.1339-09.2009.
10
beta-peptide immunization: a possible new treatment for Alzheimer disease.
Arch Neurol. 2000 Jul;57(7):934-6. doi: 10.1001/archneur.57.7.934.
引用本文的文献
1
Elongation of the C-terminal domain of an anti-amyloid β single-chain variable fragment increases its thermodynamic stability and decreases its aggregation tendency.
MAbs. 2013 Sep-Oct;5(5):678-89. doi: 10.4161/mabs.25382. Epub 2013 Jun 19.
本文引用的文献
1
Anti-NMDA-receptor encephalitis: case series and analysis of the effects of antibodies.
Lancet Neurol. 2008 Dec;7(12):1091-8. doi: 10.1016/S1474-4422(08)70224-2. Epub 2008 Oct 11.
2
Co-occurrence of Alzheimer's disease ß-amyloid and τ pathologies at synapses.
Neurobiol Aging. 2010 Jul;31(7):1145-52. doi: 10.1016/j.neurobiolaging.2008.07.021. Epub 2008 Sep 3.
3
Long-term effects of Abeta42 immunisation in Alzheimer's disease: follow-up of a randomised, placebo-controlled phase I trial.
Lancet. 2008 Jul 19;372(9634):216-23. doi: 10.1016/S0140-6736(08)61075-2.
4
Soluble oligomers of the amyloid beta-protein impair synaptic plasticity and behavior.
Behav Brain Res. 2008 Sep 1;192(1):106-13. doi: 10.1016/j.bbr.2008.02.016. Epub 2008 Feb 17.
5
Paraneoplastic syndromes of the CNS.
Lancet Neurol. 2008 Apr;7(4):327-40. doi: 10.1016/S1474-4422(08)70060-7.
6
Immunotherapy for Alzheimer's disease: attacking amyloid-beta from the inside.
Trends Immunol. 2007 Dec;28(12):511-3. doi: 10.1016/j.it.2007.09.005. Epub 2007 Nov 5.
7
Immunotherapy targeting pathological tau conformers in a tangle mouse model reduces brain pathology with associated functional improvements.
J Neurosci. 2007 Aug 22;27(34):9115-29. doi: 10.1523/JNEUROSCI.2361-07.2007.
8
Reducing endogenous tau ameliorates amyloid beta-induced deficits in an Alzheimer's disease mouse model.
Science. 2007 May 4;316(5825):750-4. doi: 10.1126/science.1141736.
9
Internalized antibodies to the Abeta domain of APP reduce neuronal Abeta and protect against synaptic alterations.
J Biol Chem. 2007 Jun 29;282(26):18895-906. doi: 10.1074/jbc.M700373200. Epub 2007 Apr 27.
10
Paraneoplastic syndromes affecting the nervous system.
Semin Oncol. 2006 Jun;33(3):270-98. doi: 10.1053/j.seminoncol.2006.03.008.
Zotero 插件